The trajectory of Viagra presents a interesting case for observers in the pharmaceutical sector. While initially a blockbuster success, producing vast sums, the exclusivity lapse and the subsequent arrival of cheaper alternatives have significantly affected income. This raises questions about the long-term viability of analogous therapeutic innovat